Research Analysts’ Recent Ratings Changes for Glaukos (GKOS)

A number of research firms have changed their ratings and price targets for Glaukos (NYSE: GKOS):

• 12/11/2024 – Glaukos had its price target raised by analysts at Wells Fargo & Company from $145.00 to $153.00. They now have an “overweight” rating on the stock.
• 12/11/2024 – Glaukos was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $162.00 price target on the stock, up previously from $132.00.
• 12/6/2024 – Glaukos is now covered by analysts at UBS Group AG. They set a “buy” rating and a $182.00 price target on the stock.
• 12/2/2024 – Glaukos was downgraded by analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating. They now have a $120.00 price target on the stock.
• 12/2/2024 – Glaukos was upgraded by analysts at Stephens to a “strong-buy” rating.
• 12/2/2024 – Glaukos had its price target raised by analysts at Stifel Nicolaus from $145.00 to $153.00. They now have a “buy” rating on the stock.
• 11/26/2024 – Glaukos had its price target raised by analysts at BTIG Research from $140.00 to $149.00. They now have a “buy” rating on the stock.
• 11/5/2024 – Glaukos had its price target raised by analysts at JPMorgan Chase & Co. from $130.00 to $145.00. They now have an “overweight” rating on the stock.
• 11/5/2024 – Glaukos had its price target raised by analysts at Wells Fargo & Company from $135.00 to $145.00. They now have an “overweight” rating on the stock.
• 10/21/2024 – Glaukos was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/17/2024 – Glaukos was given a new $140.00 price target on by analysts at Piper Sandler.
• 10/14/2024 – Glaukos had its price target raised by analysts at Truist Financial Co. from $145.00 to $152.00. They now have a “buy” rating on the stock.

Glaukos Stock Performance

Shares of GKOS stock traded up $9.20 during trading hours on Wednesday, hitting $145.58. The company’s stock had a trading volume of 224,702 shares, compared to its average volume of 567,651. The company has a 50 day moving average of $135.53 and a 200 day moving average of $126.38. The stock has a market cap of $8.03 billion, a PE ratio of -48.21 and a beta of 1.03. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12-month low of $59.58 and a 12-month high of $146.86.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. The business had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.50) EPS. On average, sell-side analysts forecast that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Insider Activity at Glaukos

In related news, COO Joseph E. Gilliam sold 2,275 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at $14,198,425.93. The trade was a 2.18 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Glaukos

Several large investors have recently made changes to their positions in GKOS. Assenagon Asset Management S.A. acquired a new position in Glaukos during the second quarter worth $6,832,000. WCM Investment Management LLC raised its position in Glaukos by 45.7% during the third quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier’s stock worth $12,721,000 after acquiring an additional 31,084 shares during the period. BNP Paribas Financial Markets raised its position in Glaukos by 186.9% during the third quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier’s stock worth $1,788,000 after acquiring an additional 8,942 shares during the period. First Turn Management LLC acquired a new position in Glaukos during the third quarter worth $12,520,000. Finally, Victory Capital Management Inc. raised its position in Glaukos by 421.8% during the third quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier’s stock worth $10,320,000 after acquiring an additional 64,031 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.